Immuneering Corp — Director's Dealing 2025

Jun 24, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-06-20

Reporting Person: Hall Brett Matthew (CHIEF SCIENTIFIC OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-20	Class A Common Stock	P	7415	$2.6999	Acquired	353311	Direct
2025-06-23	Class A Common Stock	P	6007	$2.4299	Acquired	359318	Direct

Footnotes

F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.4101 to $2.4299. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.